Search Results - Serra Lopez, Jorgina

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events

    Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events by Alserawan, Leticia, Anguera, Geòrgia, Zamora Atenza, Carlos, Serra López, Jorgina, Martínez-Martínez, Laura, Riudavets Melià, Mariona, Sullivan, Ivana, Barba Joaquin, Andrés, Majem Tarruella, Margarita, Vidal, Silvia

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Potential Role of Circulating PD-L1 + Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients

    Potential Role of Circulating PD-L1 + Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients by Anguera, Georgia, Mulet, Maria, Zamora, Carlos, Osuna-Gómez, Rubén, Barba, Andrés, Sullivan, Ivana, Serra-López, Jorgina, Cantó, Elisabet, Vidal, Silvia, Majem, Margarita

    Published in Biomedicines
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  3. 3
    Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors

    Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors by Alserawan, Leticia, Mulet, Maria, Anguera, Geòrgia, Riudavets, Mariona, Zamora, Carlos, Osuna-Gómez, Rubén, Serra-López, Jorgina, Barba Joaquín, Andrés, Sullivan, Ivana, Majem, Margarita, Vidal, Silvia

    Published in Cancers
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  4. 4
    The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents

    The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents by Zamora Atenza, Carlos, Anguera, Geòrgia, Riudavets Melià, Mariona, Alserawan De Lamo, Letícia, Sullivan, Ivana, Barba Joaquin, Andrés, Serra Lopez, Jorgina, Ortiz, M. Angels, Mulet, Maria, Vidal, Sílvia, Majem, Margarita

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: